The global xerostomia therapeutics market was valued at USD 650 million in 2021 and is expected to grow to roughly USD 950 million by 2030, with a CAGR of 3.5% during the forecast period.
Xerostomia, often known as dry mouth, refers to the symptoms or perceptions of oral dryness produced by a decrease in saliva production. This syndrome is caused by the negative effects of radioactivity in the neck and head, increased use of antianxiety medications, dehydration, diabetes, and Alzheimer’s disease. It can be treated with salivary pens or stimulants, artificial saliva, prescribed drugs, and home therapies such as drinking water and hydrating the lips.
Aside from that, practitioners should diagnose salivary glands early and use prescribed mouth moisturizing treatments, such as over-the-counter (OTC) rinse, to help lubricate the mouth. These treatments relieve pain, prevent serious complications, correct taste issues, and reduce bad breath and taste problems. As a result, xerostomia treatments are employed in a variety of hospitals and clinics to address impaired salivary gland function.
Request a sample copy of the report – https://wemarketresearch.com/reports/xerostomia-therapeutics-market/907
Xerostomia Therapeutics Market Key Company
- GlaxoSmithKline PLC
- Parnell Pharmaceuticals Inc.
- Bausch Health Companies Inc.
- 3M Company
- Quest Products Inc.
- Fresenius SE & Co. KGaA
- Hikma Pharmaceuticals PLC
- Lupin Limited
- Sun Pharmaceutical Industries Ltd
- Sanofi (Chattem, Inc.)
- Synedgen Inc. (Prisyna)
- ADVANZ PHARMA Corp. Limited
- Saliwell Ltd
- Pharmascience Inc (Pendopharm)
Xerostomia Therapeutics Market Trend
The increasing incidence of dry mouth, particularly among the elderly, as a result of radiotherapy and chemotherapy side effects, as well as the growing demand for dry mouth treatment solutions, are driving market expansion. Furthermore, the increased usage of prescription-based toothpaste, vitamin gummies, and medications to treat Sjogren’s syndrome, Alzheimer’s illness, and human immunodeficiency virus (HIV), all of which cause xerostomia, is stimulating expansion.
In accordance with this, increased consumer awareness of the need of early detection of xerostomia, major increases in healthcare spending, and the introduction of new diagnostic technologies are fueling market expansion. Furthermore, positive government measures to raise consumer awareness of xerostomia disease, its symptoms, causes, and treatments are driving market expansion. Aside from that, the simple availability of various medicinal medications, as well as ongoing research and development (R&D) operations, are contributing to a healthy market outlook.
Growth Driver
The Xerostomia Therapeutics Market is experiencing a boost in demand as oral health concerns become more prevalent. Xerostomia, often known as dry mouth, is a common side effect of many medical procedures and drugs, which contributes to its prevalence. The aging of the population, combined with the increased use of drugs that cause xerostomia, has increased the demand for effective therapies. As the prevalence of oral health disorders, such as tooth decay and gum disease, increases, so does the demand for xerostomia therapies. Patients who have dry mouth symptoms want alleviation not only for comfort, but also to avoid serious oral health consequences.
This tendency has driven R&D efforts to improve existing medications and develop novel remedies, resulting in developments in the Xerostomia Therapeutics Market. As a result, healthcare practitioners, pharmaceutical companies, and patients are focusing more on xerostomia management and therapy, opening up new business prospects.
Regional Insights
North America topped the regional category, accounting for the majority of revenue, followed by Europe. The rising prevalence of xerostomia and other dry mouth-related disorders such as rheumatoid arthritis, Sjogren’s syndrome, and HIV, together with an increase in dry mouth awareness programs, are important variables contributing to governance. For example, the Sjogren Syndrome Foundation of the United States is responsible for raising awareness and aiding patients with xerostomia in the United States and Canada.
However, Asia Pacific is expected to develop at a positive CAGR over the forecast period due to rising healthcare expenditure, more awareness-raising initiatives, and the growing prevalence of disorders such as HIV, cancer, diabetes, and Parkinson’s disease, all of which cause dry mouth. Cancer rates are rapidly rising in the Asia-Pacific area.
Developing economies, such as China and India, have developed both health and industrial strategies to encourage domestic production of cancer medications, with the goal of lowering treatment costs. Lower therapeutic costs, combined with increased cancer awareness, are expected to drive up the uptake of chemotherapy and radiotherapy. The expanding cancer burden leads to increased use of radiation and chemotherapy, as well as the dry mouth symptoms associated with these treatments. As a result, there is a greater need for therapies for xerostomia, which increases regional market growth.
Buy Now Xerostomia Therapeutics Market Report – https://wemarketresearch.com/purchase/xerostomia-therapeutics-market/907?license=single
About We Market Research
We Market Research is a leading provider of comprehensive market research solutions that assist businesses in making informed decisions and staying ahead of the competition in today’s ever-changing marketplace. With our extensive knowledge and cutting-edge methods, we assist our customers in gaining deep insights into their target markets, consumers, and competitors.
Our firm understands that great business strategies are based on accurate and actionable data. That is why we specialize in conducting in-depth research and analysis across several industries, enabling our clients to identify market trends, assess demand and supply dynamics, and identify development opportunities.
Contact us
Mr. Robbin Joseph
Corporate Sales, USA
We Market Research
USA: +1-724-618-3925
Websites: https://wemarketresearch.com/
Email: [email protected]
